Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

BMJ Case Rep. 2008:2008:bcr0620080075. doi: 10.1136/bcr.06.2008.0075. Epub 2008 Nov 20.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Drug Eruptions / drug therapy
  • Drug Eruptions / etiology
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Fatal Outcome
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors